Prof. Dr. Michael T. Heneka

Prof. Dr. Michael T. Heneka

University Professor

Weitere Informationen


1990 – 1996 Medical studies, University of Tübingen, Germany, MD thesis at the Dept. of Pharmacology and Toxicology, “summa cum laude”
1996 – 2002 Specialisation and board examination in neurology
2003 Habilitation for Neurology “Inflammatory mechanisms of Alzheimer`s disease: characterisation and development of therapeutic strategies”.

Academic Career

1996 – 1998 Postdoctoral fellow, Department of Neurology, University of Tübingen
1997 – 1998 Clinical resident, Department of Neurology, University of Tübingen
1998 – 1998 Postdoctoral fellow, University of Illinois at Chicago, Chicago, USA
1999 – 2003 Clinical resident, Department of Neurology, University of Bonn
2000 Visiting Scientist, University of Illinois at Chicago, Chicago, USA
2003 Postdoctoral fellow, Dept. of Neuroscience, Case Western Reserve University, Cleveland, USA
2004 Senior clinical fellow, Department of Neurology, University of Bonn
2004 – 2008 Full Prof. of Neurology, Head of the Molecular Neurology Unit at the Dept. of Neurology, University of Münster
Since 2007 Board member, German Ministry of Research and Education “Network of competence for neurodegenerative dementias”
Since 2007 Head, DFG-Clinical Research Center KFO 177 “Innate Immunity in Chronic Neurodegeneration”
Since 2008 Full Professor of Clinical Neuroscience, Dept. of Neurology, University of Bonn, Director of the Clinical Neurosciences Unit (CNU)
Since 2010 Head of the Neurodegeneration Outpatient Unit (KBFZ)

Memberships and professional functions

* Society for Neuroscience, American Society for Neurochemistry, International Society for Neurochemistry, German Society for Neurology. Board member, German Ministry of Research and Education “Network of competence for neurodegenerative dementias”.

* Editor, Journal of Chemical Neuroanatomy, Journal of Neurochemistry.


1998 Attempto Award, University of Tübingen
2011 Christa Lorenz-ALS-Forschungspreis
2013 Hans und Ilse Breuer Award

Most important publications

  1. Krauthausen M, Kummer MP, Zimmermann J, Reyes-Irisarri E, Terwel D, Bulic B, Müller M*,Heneka MT.* (2015) CXCR3 is critical for the Alzheimer’s-like plaque formation in APP/PS1 mice. J. Clin. Invest., 125(1):365-78. * equal contributing authors.
  2. Kummer MP, Hammerschmidt T, Martinez A, Terwel D, Eichele G, Witten A, Figura S, Stoll M, Schwartz S, Pape HC, Schultze JL, Weinshenker D, Heneka MT Ear2 deletion causes early memory and learning deficits in APP/PS1 mice (2014) J. Neurosci., 34(26): 8845-8854.
  3. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT (2013) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature., 493: 674-678.
  4. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. (2012) PPARγ/RXRα induced and CD36 mediated microglial Aβ phagocytosis results in cognitive improvement in APP/PS1 mice, J Neurosci., 32(48): 17321-31.
  5. Kummer MP, Hermes M, Delekarte A, Hammerschmidt T, Kumar S, Terwel D, Walter J, Pape HC, König, S, Roeber S, Jessen F, Klockgether T, Korte M, Heneka MT. (2011) Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. Neuron 71: 833-844.
  6. Heneka MT, Nadrigny F, Regen T, Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch U, Kummer MP (2010) Locus ceruleus controls Alzheimer disease pathology by modulating microglial functions through norepinephrine Proc. Natl. Acad. Sci. U.S.A., 107: 6058-6063.
  7. Sastre M, Dewachter I, Roßner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, Van Leuven F, Heneka MT (2006) NSAIDs repress BACE1 gene promoter activity by the activation of PPARγ. Proc. Natl. Acad. Sci. U.S.A.103: 443-448.
  8. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Cuiperi K, O´Banion MK, Klockgether T, Van Leuven F, Landreth GE. (2005) Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces inflammation and Aβ1-42 levels in APP V717I transgenic mice. Brain, 128: 1442-1453.
  9. Feinstein DL, Galea E, Gavriluyk V, Brosnan CF, Whitacre CC; Dumitrescu-Ozimek L, Landreth GE, Weinberg G, Heneka MT. (2002) PPAR-γ agonists prevent experimental autoimmune encephalitis. Ann. Neurol., 51: 694-702.
  10. Heneka MT, Löschmann PA, Osswald H. (1997) Polymerized hemoglobin restores cardiovascular and kidney function in endotoxin induced shock in the rat. J. Clin. Invest., 99: 47-54.